Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.55 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.53 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15017817 | 1.00 | CYP1A2 (0.62) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| SCHEMBL3637068 | 0.98 | CYP1A2 (0.66) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| SCHEMBL3471627 | 0.98 | CYP1A2 (0.66) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| Hydrochloric Acid SCHEMBL3600790 | 0.98 | CYP1A2 (0.61) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| Hydrochloric Acid SCHEMBL18641313 | 0.98 | CYP1A2 (0.61) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| SCHEMBL8514562 | 0.96 | CYP1A2 (0.58) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| Hydrochloric Acid SCHEMBL8535248 | 0.94 | CYP1A2 (0.56) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| SCHEMBL28777272 | 0.85 | RPS6KB1 (0.48) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| SCHEMBL17086150 | 0.85 | CYP1A2 (0.59) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| SCHEMBL15797439 | 0.84 | CYP1A2 (0.50) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017048962-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-9359346-B2 | Benzamide derivative and use thereof | VIVOZON, INC. (KR) | 2016-06-07 | — | — | US | disclosed |
| US-9359346-B2 | Benzamide derivative and use thereof | VIVOZON, INC. (KR) | 2016-06-07 | — | — | US | disclosed |
| EP-3013812-A2 | KAPPA OPIOID AGONISTS AND USES THEREOF | Nektar Therapeutics (US) | 2016-05-04 | — | — | EP | disclosed |
| EP-2760862-B1 | 6-(4-HYDROXY-PHENYL)-3-ALKYL-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS | SANOFI SA (FR) | 2015-10-21 | — | — | EP | disclosed |
| US-20150073136-A1 | PYRAZINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
| WO-2014210436-A2 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS (US) | 2014-12-31 | — | — | WO | disclosed |
| EP-1799684-B1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARM INC (US) | 2014-12-03 | — | — | EP | disclosed |
| US-8889692-B2 | Pyrazinone derivatives, pharmaceutically acceptance salts thereof and their uses | ASTRAZENECA AB (SE) | 2014-11-18 | — | — | US | disclosed |
| US-20140336378-A1 | NOVEL BENZAMIDE DERIVATIVE AND USE THEREOF | VIVOZON, INC. (KR) | 2014-11-13 | — | — | US | disclosed |
| EP-1968568-A2 | INHIBITORS OF Akt ACTIVITY | SmithKline Beecham Corporation (US) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007147109-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
| EP-1863805-A1 | PYRIMIDINE COMPOUNDS HAVING TIE2 (TEK) INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2007-12-12 | — | — | EP | disclosed |
| US-20070197522-A1 | Dpp-iv inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197522-A1 | Dpp-iv inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007076423-A2 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2006082373-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006018284-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | NOVARTIS AG (CH) | 2006-02-23 | — | — | WO | disclosed |
| WO-2005095343-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005058298-A2 | FK228 ANALOGS AND THEIR USE AS HDAC-INHIBITORS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336378-A1 | NOVEL BENZAMIDE DERIVATIVE AND USE THEREOF | TRPV1, TRPA1, TRPV5 | CYP1A2 755/4885CYP2C19 569/4885CYP3A4 1435/4885 |
| US-20070197522-A1 | Dpp-iv inhibitors | DPP7, DPP4, DPP3 | CYP1A2 1188/4885CYP2C19 655/4885CYP3A4 267/4885 |
| US-20150073136-A1 | PYRAZINONE DERIVATIVES | CYP3A7, CYP3A4, CYP2D6 | CYP1A2 9/4885CYP2C19 5/4885CYP3A4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.